81 citations
,
February 2000 in “Anti-cancer drugs” In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.
522 citations
,
January 2001 in “Cancer investigation” This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.
68 citations
,
March 2002 in “Journal of pharmaceutical sciences” This study found that nonionic liposomes were the most effective vehicle for delivering reporter genes into the skin of rat pups, compared to other liposome and nonliposome formulations.
58 citations
,
December 2012 in “Aaps Pharmscitech” This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.
30 citations
,
December 2019 in “PLoS ONE” This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.